Press Releases

News Category

Year

Supernus Announces FDA Approval of Qelbree™ (SPN-812) for the Treatment of ADHD

Qelbree (viloxazine extended-release capsules) represents the first novel non-stimulant treatment for ADHD in a decade Supernus plans to make Qelbree available in the U.S. in 2Q 2021 ROCKVILLE, Md. , April 02, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc.

Posted: April 2, 2021

PDF Version

Supernus to Present at Cowen Healthcare Conference

ROCKVILLE, Md. , Feb. 26, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that Jack Khattar , President and CEO of Supernus

Posted: February 26, 2021

PDF Version

Supernus Announces Fourth Quarter and Full Year 2020 Financial Results

Full year 2020 total revenues of $520.4 million , a 32% increase compared to 2019 Full year 2020 operating earnings of $173.7 million , a 17% increase compared to 2019 SPN-812 NDA assigned an early April 2021 PDUFA date Positive results from Phase III study for SPN-812 in adults with ADHD announced

Posted: February 25, 2021

PDF Version

Supernus to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call

ROCKVILLE, Md. , Feb. 23, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report business

Posted: February 23, 2021

PDF Version

Supernus Receives FDA Notice Assigning Early April 2021 PDUFA Date for SPN-812 NDA

ROCKVILLE, Md. , Feb. 22, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that it received notice from the U.S.

Posted: February 22, 2021

PDF Version

Supernus Resubmits New Drug Application for SPN-812 for the Treatment of ADHD in Pediatric Patients

ROCKVILLE, Md. , Feb. 08, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced it has resubmitted its New Drug Application

Posted: February 8, 2021

PDF Version

Supernus to Present at J.P. Morgan 39th Annual Healthcare Conference

ROCKVILLE, Md. , Jan. 06, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company's management will present at the

Posted: January 6, 2021

PDF Version